Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Tango Therapeutics Inc
TNGXCurrent price
3.92 USD
+0.27 USD (+7.40%)
Last closed
3.56 USD
Company
www.tangotx.com
ISIN
US87583X1090
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
316 883 104 USD
Yield for 12 month
-45.82 %
1Y
3Y
5Y
10Y
15Y
TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. Address: 201 Brookline Avenue, Boston, MA, United States, 02215
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12.5 USDP/E ratio
–Dividend Yield
–Current Year
+36 527 000 USD
Last Year
+24 860 000 USD
Current Quarter
+11 607 000 USD
Last Quarter
+19 875 000 USD
Current Year
+34 112 000 USD
Last Year
+24 860 000 USD
Current Quarter
+11 607 000 USD
Last Quarter
+19 243 000 USD
Key Figures TNGX
1 year
3 years
5 years
10 years
EBITDA
-137 202 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-22.37 %
PEG Ratio
–
Return On Equity TTM
-48.79 %
Wall Street Target Price
12.5 USD
Revenue TTM
43 383 000 USD
Book Value
2.13 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
8.2 %
Dividend Yield
–
Gross Profit TTM
-81 046 000 USD
Earnings per share
-1.15 USD
Diluted Eps TTM
-1.15 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-284.43 %
Dividend Analytics TNGX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TNGX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation TNGX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
1.4114
Price Sales TTM
7.3043
Enterprise Value EBITDA
-0.9077
Price Book MRQ
1.3827
Financials TNGX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators TNGX
For 52 weeks
2.7 USD
13.01 USD
50 Day MA
7.41 USD
Shares Short Prior Month
10 813 285
200 Day MA
8.75 USD
Short Ratio
8.71
Shares Short
8 904 706
Short Percent
15.34 %
BeatStart